Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors.
Zongertinib in NCI-H-2170 HER2 wt amp, NCI-H2170 HER2 YVMA, A431 EGFR wt amp, BAF3 HER2 WT, BAF3 HER2 YVMA and BAF3 EGF dep. The IC50 values that inhibits cell proliferation are 6 nM, 33 nM, >5000 nM, 1 nM, 16 nM, and 1540 nM, respectively[2].
References:
[1]. WHO Drug Informat ion - World Health Organization (WHO). [2]. Wilding Birgit, et al. Synthesis of diazino-pyrimidines as anticancer agents: World Intellectual Property Organization, WO2021213800. 2021-10-28. [3]. Li S, et al. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers (Basel). 2023 May 24;15(11):2899.